Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H17F3N2O4S |
| Molecular Weight | 426.409 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CC(O)=O)C2=CC=CN=C2N1CC3=CC=C(C=C3C(F)(F)F)S(C)(=O)=O
InChI
InChIKey=GFPPXZDRVCSVNR-UHFFFAOYSA-N
InChI=1S/C19H17F3N2O4S/c1-11-15(9-17(25)26)14-4-3-7-23-18(14)24(11)10-12-5-6-13(29(2,27)28)8-16(12)19(20,21)22/h3-8H,9-10H2,1-2H3,(H,25,26)
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers. | 2016 Jul |
|
| Fevipiprant (QAW039), a Slowly Dissociating CRTh2 Antagonist with the Potential for Improved Clinical Efficacy. | 2016 May |
|
| An evaluation of fevipiprant for the treatment of asthma: a promising new therapy? | 2018 Dec |
Sample Use Guides
Fevipiprant (QAW039) is currently in development for the treatment of allergic diseases. [3H]-QAW039 displayed high affinity for the human CRTh2 receptor (1.14 +/- 0.44 nM) expressed in Chinese hamster ovary cells, the binding being reversible and competitive with the native agonist prostaglandin D2.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB12011
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY | |||
|
C166588
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY | |||
|
BC-37
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY | |||
|
872365-14-5
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY | |||
|
CHEMBL3137332
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY | |||
|
9682
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY | |||
|
100000174166
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY | |||
|
2PEX5N7DQ4
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY | |||
|
Fevipiprant
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY | |||
|
DTXSID501336031
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY | |||
|
23582412
Created by
admin on Sat Dec 16 08:19:31 UTC 2023 , Edited by admin on Sat Dec 16 08:19:31 UTC 2023
|
PRIMARY |
